Drug Profile
Nazartinib - Novartis Oncology
Alternative Names: EGF-816; EGFRmut-TKI EGF816; Nazartinib mesylate; NVP EGF816 AGALatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Massachusetts General Hospital; Novartis; Novartis Oncology
- Class Antineoplastics; Azepines; Benzimidazoles; Pyridines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Discontinued Solid tumours
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Canada (PO, Capsule)
- 28 May 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Germany (PO, Capsule)
- 28 May 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Hong Kong (PO, Capsule)